Sphenopalatine Block for Treatment of Migraine Headache| Biomed GridJournal
: American Journal of Biomedical Science & Research (Vol.2, No. 5)
Publication Date: 2019-04-25
Authors : Barry J Kraynack;
Page : 202-203
Keywords : Biomedical Science and Research Journals; biomedical open access journals; biomedical research journals; Biomed Grid; open access journals of biomedical science;
Source : Download Find it from : Google Scholar
Migraine is a common headache and a leading cause of disability worldwide . Chronic migraine (CM) burdens patients due to the headache and debilitating associated symptoms and through disability high economic costs. CM patients meet diagnostic criteria and have a minimum of headaches and symptoms 8 days a month or headaches on 15 days a month. A complete, detailed history and an in-depth physical examination with the emphasis on neurologic aspects is required in order to differentiate CM from other causes of headache. If indicated, other diagnostic tests may be required . A multifaceted approach is used to eliminate risk factors and headache triggers. Prophylaxis and abortive approaches can be applied. Use of pharmacologic agents for the acute/chronic treatment of migraine may be limited by adverse side effects, variability if effect and efficacy, or contraindications, allergies or untoward drug -drug interactions. These factors contribute to chronicity of the headache and medication overuse headache .
Historically, we have considered migraine as a self-limited pain disorder that is episodic. More recently however, CM has become an end stage disorder of episodic migraine (EM). The International Headache Society suggests that CM is a complication of EM [4-6]. Indeed, other current evidence indicates that migraine may be a chronic progressive disorder characterized by escalating frequency of headache attacks, often termed transformed migraine. Munakata et al.  reported that transformed migraine patients missed much more work or school time. Productivity was significantly reduced. Average per-person annual total costs were 4.4-fold greater for those with transformed migraine ($7750) versus those with EM ($1757). Transformed migraine extracts a significant economic toll.
Last modified: 2019-05-31 13:48:48